摘要
目的 回顾性分析新生儿病房1998-2012年来诊断为新生儿呼吸窘迫综合征(respiratory distress syndrome, RDS)的早产儿病例, 总结在治疗措施方面的进展。方法 回顾性病例对照研究, 1998年1月-2012年12月本院新生儿重症监护病房(NICU)收治的<34周新生儿呼吸窘迫综合征早产儿病例, 记录母孕期情况和围产期情况, 出生史和采用呼吸支持方式(有创或无创呼吸支持), 是否应用肺表面活性物质(pulmonary surfactant, PS), 用药剂量以及患儿的合并症和结局。结果 自1998年1月-2004年12月为A组, 63例;2005年1月-2012年12月病例为B组, 151例。B组患儿出生体重[(1 284.50±252.15)g]明显低于A组[(1 424.27±329.44)g](t=3.292, P<0.001), 分娩前应用激素促进肺成熟的病例数明显增加(B组139例, 92.1%;A组44例, 69.8%;χ2=17.704, P<0.001);B组应用PS总量为(195.00±59.87) mg, A组中应用PS总量为(169.66±57.97)mg, 两组间差异有统计学意义(P=0.041);计算PS与体重比值, B组为(147.71±42.09)mg/kg, A组为(115.86±37.11)mg/kg, 差异显著(P<0.01)。B组85(70.8%)应用有创呼吸支持, 较A组39例(90.7%), 显著降低(χ2=6.86, P<0.01)。B组33例(27.5%)诊断支气管肺发育不良(BPD), 较A组4例(9.3%)显著增高(χ2=5.97, P=0.02)。住院天数、NICU住院天数、氧疗天数都是B组显著长于A组。A组12例死亡, 病死率27.9%, 而B组14例死亡, 病死率11.7%, 两组比较差异有统计学意义(χ2=6.23, P=0.01)。结论 在过去十余年来, 随着分娩前应用激素促肺成熟及外源性表面活性物质的引入, 采用适宜的呼吸支持方式, 使越来越多的RDS早产儿得以存活。
Abstract
Objective To study changes of treatment in preterm infants with respiratory distress syndrome (RDS) during 1998-2012. Methods Retrospective observational study of infants, <34 weeks gestation, born between January 1998 and December 2012.A group was the cases during the first 7 years(n=63), and B group was the cases during the next 8 years(n=151).Perinatal data, birth history treatment (including respiratory support, surfactant therapy and doses), complications and outcomes were compared. Results The birth weight of B group was (1 284.50±252.153)g, significantly lower than A group [(1 424.27±329.44)g](t=3.292, P<0.001).The amount of surfactant in group was (169.66±57.97) mg, significantly lower than that of B group [(195.00±59.87) mg](P=0.041).The requirement of intubation ventilation support in A group was 39 cases (90.7%), higher than 85 cases in B group (70.8%)(χ2=6.86, P<0.01).In group B, 33 cases (27.5%) developed BPD, which was more than 4 cases (9.3%) in A group (χ2=5.97, P=0.02).The length of hospitalization, NICU stay and oxygen dependence in B group were longer than A group.The mortality of B group was lower than A group, 11.7% versus 27.9% (χ2=6.23, P=0.01). Conclusion In the last decades, exogenous surfactant replacement has been established as an effective and safe therapy in RDS preterm infants.
关键词
新生儿呼吸窘迫综合征 /
肺表面活性物质 /
早产儿
Key words
respiratory distress syndrome /
surfactant /
preterm infants
韩彤妍, 童笑梅, 朴梅花, 李在玲, 崔蕴璞, 汤亚南, 常艳美.
1998-2012年早产儿呼吸窘迫综合征的临床治疗[J]. 中国儿童保健杂志. 2014, 22(4): 416-419 https://doi.org/10.11852/zgetbjzz2014-22-04-25
HAN Tong-yan, TONG Xiao-mei, PIAO Mei-hua, LI Zai-ling, CUI Yun-pu, TANG Ya-nan, CHANG Yan-mei..
Retrospective study of preterm infants with respiratory distress syndrome during 1998-2012.[J]. Chinese Journal of Child Health Care. 2014, 22(4): 416-419 https://doi.org/10.11852/zgetbjzz2014-22-04-25
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Teksam O, Kale G.The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome[J].Pathol Res Pract, 2009, 205(1):35-41.
[2] Halliday HL.Surfactants:past, present and future[J].J Perinatol, 2008, 28(S):47-56.
[3] Sweet DG, Carnielli V, Greisen G, et al.European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update[J].Neonatology, 2010, 97:402-417.
[4] Nkadi PO, Merritt TA, Pillers DM.An overview of pulmonary surfactant in the neonate:genetics, metabolism, and the role of surfactant in health and disease[J].Mol Genet Metab, 2009, 97(2):95-101.
[5] Engle WA.The Committee on Fetus and Newborn, Surfactant-replacement therapy for respiratory distress in the preterm and term neonate[J].Pediatrics, 2008, 121:419-432.
[6] 李杰, 樊寻梅, 宋国维, 等.肺表面活性制剂治疗新生儿呼吸窘迫综合征多中心临床观察[J].中华儿科杂志, 2000, 38(6):344-347.
[7] Soll R, Ozek E.Prophylactic protein-free synthetic surfactant for preventing morbidity and mortality in preterm infants[J].Cochrane Database Syst Rev, 2010, 20(1):CD001079.
[8] Yen TA, Wang CC, Hsieh WS, et al.Short-term outcome of pulmonary hemorrhage in very-low-birth-weight preterm infants[J].Pediatr Neonatol, 2013, 54(5):330-4.
[9] Strauss T, Rozenzweig N, Rosenberg N, et al.Surfactant impairs coagulation in-vitro:a risk factor for pulmonary hemorrhage?[J].Thromb Res, 2013, 132(5):599-603.
[10] Finer NN.Surfactant use for neonatal lung injury:beyond respiratory distress syndrome[J].Paediatric Respiratory Reviews, 2004, 5(S):289-297.
PDF(547 KB)
